Zobrazeno 1 - 10
of 25
pro vyhledávání: '"John G. Damrath"'
Autor:
Michael P. Liesen, Megan L. Noonan, Pu Ni, Rafiou Agoro, Julia M. Hum, Erica L. Clinkenbeard, John G. Damrath, Joseph M. Wallace, Elizabeth A. Swallow, Matthew R. Allen, Kenneth E. White
Publikováno v:
Physiological Reports, Vol 10, Iss 11, Pp n/a-n/a (2022)
Abstract Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis‐dependent CKD, and for iron deficiency anemia (IDA) in non‐dialysis CKD. Elevated Pi and IDA both lead to increa
Externí odkaz:
https://doaj.org/article/d97139ec9c584ca49c400a203575d55c
Autor:
John G Damrath, Neal X Chen, Corinne E Metzger, Shruthi Srinivasan, Kalisha O'Neill, Annabel Biruete, Keith G Avin, Joseph M Wallace, Matthew R Allen, Sharon M Moe
Publikováno v:
JBMR Plus, Vol 6, Iss 3, Pp n/a-n/a (2022)
ABSTRACT Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroi
Externí odkaz:
https://doaj.org/article/84eb20bab12e481584fe0301a35fc26d
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2021)
Osteocytes make up 90–95% of the cellular content of bone and form a rich dendritic network with a vastly greater surface area than either osteoblasts or osteoclasts. Osteocytes are well positioned to play a role in bone homeostasis by interacting
Externí odkaz:
https://doaj.org/article/0317f2351d2845a0aef24daf6cf0d948
Publikováno v:
Curr Opin Nephrol Hypertens
PURPOSE OF REVIEW: Chronic kidney disease (CKD) affects over 15% of Americans and results in an increased risk of skeletal fractures and fracture-related mortality. However, there remain great challenges in estimating fracture risk in CKD patients, a
Publikováno v:
Bone. 165
Diabetes and chronic kidney disease (CKD) consistently rank among the top ten conditions in prevalence and mortality in the United States. Insulin-dependent diabetes (IDD) and CKD each increase the risk of skeletal fractures and fracture-related mort
Autor:
null John G. Damrath, null Neal X. Chen, null Corinne E. Metzger, null Shruthi Srinivasan, null Kalisha O’Neill, null Annabel Biruete, null Keith G. Avin, null Joseph M. Wallace, null Matthew R. Allen, null Sharon M. Moe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bd452f4faf9be01da7824a304e9c03d
https://doi.org/10.1002/jbm4.10600/v2/response1
https://doi.org/10.1002/jbm4.10600/v2/response1
Autor:
John G Damrath, Neal X Chen, Corinne E Metzger, Shruthi Srinivasan, Kalisha O'Neill, Annabel Biruete, Keith G Avin, Joseph M Wallace, Matthew R Allen, Sharon M Moe
Publikováno v:
JBMR plus. 6(3)
Chronic kidney disease-mineral and bone disorder (CKD-MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypo
Autor:
Jennifer Hatch, Joseph M. Wallace, Alexis N. Pulliam, John G Damrath, Madicyn J. Hinton, Alycia G. Berman, Katherine M. Powell
Publikováno v:
Connect Tissue Res
Raloxifene (RAL) is a selective estrogen receptor modulator (SERM) that has previously been shown to cause acellular benefits to bone tissue. Due to these improvements, RAL was combined with targeted tibial loading to assess if RAL treatment during p
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 11 (2021)
Frontiers in Endocrinology, Vol 11 (2021)
Osteocytes make up 90–95% of the cellular content of bone and form a rich dendritic network with a vastly greater surface area than either osteoblasts or osteoclasts. Osteocytes are well positioned to play a role in bone homeostasis by interacting